SEC Stock Data Quick Answer Abpro Holdings, Inc. reported Net Income of $2.82 million for fiscal year 2023. Abpro Holdings, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2023 $2.82M +218.1% 2022 $886.9K — Quarterly Net Income Quarter Ending Net Income YoY QoQ March 31, 2025 -$3.89M -1345.8% -1060.0% September 30, 2024 -$335.1K -650.8% … Read more
Quick Answer Abpro Holdings, Inc. reported Total Revenue of $183.0 thousand for fiscal year 2024. Abpro Holdings, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2024 $183.0K +50.0% 2023 $122.0K — Abpro Holdings, Inc. showed an increase of +50.0% in Total Revenue compared to the prior fiscal year. Over the 2023–2024 … Read more
Quick Answer Abpro Holdings, Inc. reported Total Revenue of $183.0 thousand for fiscal year 2024. Abpro Holdings, Inc. — Key Financials by Year Metric 2024 2023 2022 2021 Total Revenue $183.0K+50.0% $122.0K — — Net Income — $2.82M+218.1% $886.9K — Diluted EPS -$0.74-21.3% -$0.61 — — Total Assets $4.66M+38.9% $3.35M-98.9% $310.56M+85839.3% $361.4K Cash and Equivalents … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported Shares Outstanding of 60.58 million shares for fiscal year 2025. Acumen Pharmaceuticals, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 60.58M +0.8% 2024 60.09M +3.8% 2023 57.91M +41.2% 2022 41.03M +1.4% 2021 40.47M +9556.6% 2020 419,124 — Quarterly Shares Outstanding Quarter Ending Shares Outstanding … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported Operating Income of -$123.83 million for fiscal year 2025. Acumen Pharmaceuticals, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$123.83M -8.6% 2024 -$114.02M -86.5% 2023 -$61.14M -35.2% 2022 -$45.24M -131.0% 2021 -$19.58M -147.5% 2020 -$7.91M — Quarterly Operating Income Quarter Ending Operating Income YoY … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported R&D Expense of $104.89 million for fiscal year 2025. Acumen Pharmaceuticals, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $104.89M +11.8% 2024 $93.80M +121.7% 2023 $42.32M +30.8% 2022 $32.36M +163.0% 2021 $12.30M +53.9% 2020 $8.00M — Quarterly R&D Expense Quarter Ending R&D Expense YoY … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported Stockholders Equity of $70.43 million for fiscal year 2025. Acumen Pharmaceuticals, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $70.43M -61.3% 2024 $181.82M -31.9% 2023 $266.97M +41.4% 2022 $188.78M -16.2% 2021 $225.18M +1311.2% 2020 -$18.59M -62.8% 2019 -$11.42M — Quarterly Stockholders Equity Quarter Ending … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported Long-Term Debt of $22.40 million for fiscal year 2025. Acumen Pharmaceuticals, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $22.40M -23.9% 2024 $29.42M -1.6% 2023 $29.90M — 2022 $0.00 — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ September 30, 2025 $27.05M -8.8% … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported Cash and Equivalents of $53.99 million for fiscal year 2025. Acumen Pharmaceuticals, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $53.99M +51.5% 2024 $35.63M -46.7% 2023 $66.89M -48.6% 2022 $130.10M +6.5% 2021 $122.16M +179.1% 2020 $43.78M +568.1% 2019 $6.55M — Quarterly Cash … Read more
Quick Answer Acumen Pharmaceuticals, Inc. reported Total Assets of $122.83 million for fiscal year 2025. Acumen Pharmaceuticals, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $122.83M -48.6% 2024 $238.99M -22.9% 2023 $310.12M +57.8% 2022 $196.59M -14.6% 2021 $230.33M +418.4% 2020 $44.43M — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more